STDY / SteadyMed Ltd. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

STDY / SteadyMed Ltd. 15-12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36889 SteadyMed Ltd. (Exact name of registrant as specified in its chart

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated September 7, 2018, with respect to the ordinary shares of SteadyMed Ltd.

STDY / SteadyMed Ltd. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* SteadyMed Ltd. (Name of Issuer) Ordinary Shares, nominal value NIS 0.01 per share (Title of Class of Securities) M84920103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VI LLC 601 Lex

STDY / SteadyMed Ltd. POS AM

As filed with the Securities and Exchange Commission on August 30, 2018 Registration No.

STDY / SteadyMed Ltd. S-8 POS

As filed with the Securities and Exchange Commission on August 30, 2018 Registration No.

STDY / SteadyMed Ltd. S-8 POS

As filed with the Securities and Exchange Commission on August 30, 2018 Registration No.

STDY / SteadyMed Ltd. POS AM

As filed with the Securities and Exchange Commission on August 30, 2018 Registration No.

STDY / SteadyMed Ltd. POS AM

As filed with the Securities and Exchange Commission on August 30, 2018 Registration No.

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2018 SteadyMed Ltd.

SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial Results

Exhibit 99.1 SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial Results SAN RAMON, Calif., August 14, 2018 — SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its financial resu

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2018 (June 30, 2018) SteadyMed Ltd.

STDY / SteadyMed Ltd. 10-Q (Quarterly Report)

10-Q 1 a18-14073110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss

STDY / SteadyMed Ltd. / FEDERATED INVESTORS INC /PA/ Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) STEADYMED, LTD. (Name of Issuer) COMMON STOCK (Title of Class of Securities) M84920103 (CUSIP Number) July 31, 2018 (Date of Event Which Requires Filing of this Statement

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2018 SteadyMed Ltd.

STDY / SteadyMed Ltd. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd.

Exhibit 99.1 HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd. SILVER SPRING, Md. and SAN RAMON, Calif, July 20, 2018: United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) relating to United Therapeut

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2018 SteadyMed Ltd.

STDY / SteadyMed Ltd. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2018 SteadyMed Ltd.

STDY / SteadyMed Ltd. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2018 SteadyMed Ltd.

STDY / SteadyMed Ltd. DEFM14A

Use these links to rapidly review the document Table of Contents Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

STDY / SteadyMed Ltd. / FEDERATED INVESTORS INC /PA/ Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) STEADYMED, LTD. (Name of Issuer) COMMON STOCK (Title of Class of Securities) M84920103 (CUSIP Number) May 31, 2018 (Date of Event Which Requires Filing of this Statement)

STDY / SteadyMed Ltd. PREM14A

Use these links to rapidly review the document Table of Contents Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

STDY / SteadyMed Ltd. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36889 St

SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results

Exhibit 99.1 SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results SAN RAMON, Calif., May 15, 2018 — SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its financial results

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a18-1353418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2018 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel 001-36889 Not applicable (State or other jurisdiction of incorporati

STDY / SteadyMed Ltd. / Stonepine Capital Management, LLC Passive Investment

SC 13G 1 steadymed13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SteadyMed Ltd. (Name of Issuer) Ordinary Shares, nominal value NIS 0.01 per share (Title of Class of Securities) M84920103 (CUSIP Number) May 3, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate b

STDY / SteadyMed Ltd. / United Therapeutics Corp - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 SteadyMed Ltd. (Name of Issuer) Ordinary Shares, nominal value NIS 0.01 per share (Title of Class of Securities) M84920103 (CUSIP Number) United Therapeutics Corporation 1040 Spring Street Silver Spring, MD 20910 (301) 608-9292 (Name, Address and Telephone Number of Person

STDY / SteadyMed Ltd. / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* SteadyMed Ltd. (Name of Issuer) Ordinary Shares, nominal value NIS 0.01 per share (Title of Class of Securities) M84920103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VI LLC 601 Lex

JOINT FILING AGREEMENT

EX-99.1 2 ss90637ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated May 1, 2018, with respect to the ordinary shares of SteadyMed Ltd. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2018 SteadyMed Ltd.

AGREEMENT AND PLAN OF MERGER UNITED THERAPEUTICS CORPORATION, DANIEL 24043 ACQUISITION CORP. LTD. STEADYMED LTD. Dated as of April 29, 2018

EX-2.1 2 a18-124341ex2d1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among UNITED THERAPEUTICS CORPORATION, DANIEL 24043 ACQUISITION CORP. LTD. and STEADYMED LTD. Dated as of April 29, 2018 Table of Contents Page Article I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effects of the Merger 3 Section 1.5 Articles of Association of the C

FORM OF CONTINGENT VALUE RIGHTS AGREEMENT

Exhibit 2.2 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [·] (this “Agreement”), is entered into by and between United Therapeutics Corporation, a Delaware corporation (the “Parent”) and [·], as rights agent (the “Rights Agent”). RECITALS WHEREAS, SteadyMed Ltd., a company organized under the laws of the State of Israel (the “Company”), Parent and D

STEADYMED LTD. AMENDMENT NO. 1 TO WARRANT

Exhibit 10.2 STEADYMED LTD. AMENDMENT NO. 1 TO WARRANT THIS AMENDMENT NO. 1 (this “Amendment”) to that certain Warrant, dated as of [·], issued to [·] (including any permitted transferee or assignees of such Warrant, the “Warrant Holder”) and representing a right to subscribe for the purchase from SteadyMed Ltd., an Israeli incorporated company (the “Company”), [·] Shares at a price per Share equa

UNITED THERAPEUTICS TO ACQUIRE STEADYMED LTD.

Exhibit 99.1 UNITED THERAPEUTICS TO ACQUIRE STEADYMED LTD. Silver Spring, MD and San Ramon, CA, April 30, 2018: United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the a

FORM OF VOTING AGREEMENT

Exhibit 2.3 FORM OF VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of April 29, 2018, by and among United Therapeutics Corporation, a Delaware corporation (“Parent”), and each Person identified on Exhibit A attached hereto (the “Shareholders” and each a “Shareholder”). WITNESSETH: WHEREAS, Parent, Daniel 24043 Acquisition Corp Ltd., a company organized under

STEADYMED LTD. AMENDMENT NO. 1 TO WARRANT

EX-10.1 5 a18-124341ex10d1.htm EX-10.1 Exhibit 10.1 STEADYMED LTD. AMENDMENT NO. 1 TO WARRANT THIS AMENDMENT NO. 1 (this “Amendment”) to that certain Warrant, dated as of [·], issued to [·] (including any permitted transferee or assignees of such Warrant, the “Warrant Holder”) and representing a right to subscribe for the purchase from SteadyMed Ltd., an Israeli incorporated company (the “Company”

STDY / SteadyMed Ltd. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

STEADYMED LTD. AMENDMENT NO. 1 TO WARRANT

EX-10.1 5 a18-124341ex10d1.htm EX-10.1 Exhibit 10.1 STEADYMED LTD. AMENDMENT NO. 1 TO WARRANT THIS AMENDMENT NO. 1 (this “Amendment”) to that certain Warrant, dated as of [·], issued to [·] (including any permitted transferee or assignees of such Warrant, the “Warrant Holder”) and representing a right to subscribe for the purchase from SteadyMed Ltd., an Israeli incorporated company (the “Company”

STDY / SteadyMed Ltd. 8-K

DEFA14A 1 a18-1243418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2018 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel 001-36889 Not applicable (State or other jurisdiction of incor

FORM OF CONTINGENT VALUE RIGHTS AGREEMENT

EX-2.2 3 a18-124341ex2d2.htm EX-2.2 Exhibit 2.2 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [·] (this “Agreement”), is entered into by and between United Therapeutics Corporation, a Delaware corporation (the “Parent”) and [·], as rights agent (the “Rights Agent”). RECITALS WHEREAS, SteadyMed Ltd., a company organized under the laws of the State of

UNITED THERAPEUTICS TO ACQUIRE STEADYMED LTD.

EX-99.1 7 a18-124341ex99d1.htm EX-99.1 Exhibit 99.1 UNITED THERAPEUTICS TO ACQUIRE STEADYMED LTD. Silver Spring, MD and San Ramon, CA, April 30, 2018: United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additi

STEADYMED LTD. AMENDMENT NO. 1 TO WARRANT

Exhibit 10.2 STEADYMED LTD. AMENDMENT NO. 1 TO WARRANT THIS AMENDMENT NO. 1 (this “Amendment”) to that certain Warrant, dated as of [·], issued to [·] (including any permitted transferee or assignees of such Warrant, the “Warrant Holder”) and representing a right to subscribe for the purchase from SteadyMed Ltd., an Israeli incorporated company (the “Company”), [·] Shares at a price per Share equa

AGREEMENT AND PLAN OF MERGER UNITED THERAPEUTICS CORPORATION, DANIEL 24043 ACQUISITION CORP. LTD. STEADYMED LTD. Dated as of April 29, 2018

EX-2.1 2 a18-124341ex2d1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among UNITED THERAPEUTICS CORPORATION, DANIEL 24043 ACQUISITION CORP. LTD. and STEADYMED LTD. Dated as of April 29, 2018 Table of Contents Page Article I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effects of the Merger 3 Section 1.5 Articles of Association of the C

FORM OF VOTING AGREEMENT

EX-2.3 4 a18-124341ex2d3.htm EX-2.3 Exhibit 2.3 FORM OF VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of April 29, 2018, by and among United Therapeutics Corporation, a Delaware corporation (“Parent”), and each Person identified on Exhibit A attached hereto (the “Shareholders” and each a “Shareholder”). WITNESSETH: WHEREAS, Parent, Daniel 24043 Acquisition C

SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results Company on Track for Trevyent™ NDA Resubmission

EX-99.1 2 a18-93831ex99d1.htm EX-99.1 Exhibit 99.1 SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results Company on Track for Trevyent™ NDA Resubmission SAN RAMON, Calif., March 30, 2018 — SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a18-938318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2018 (March 30, 2018) SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel 001-36889 Not applicable (State or other jurisdict

STEADYMED LTD. LIST OF SUBSIDIARIES

QuickLinks - Click here to rapidly navigate through this document Exhibit 21.1 STEADYMED LTD. LIST OF SUBSIDIARIES Subsidiaries Incorporation SteadyMed Therapeutics, Inc. Delaware, United States SteadyMed U.S. Holdings, Inc. Delaware, United States QuickLinks STEADYMED LTD. LIST OF SUBSIDIARIES

STDY / SteadyMed Ltd. 10-K (Annual Report)

10-K 1 a2235047z10-k.htm 10-K Use these links to rapidly review the document TABLE OF CONTENTS STEADYMED LTD. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2017 IN U.S. DOLLARS INDEX Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

STDY / SteadyMed Ltd. / Flynn James E Passive Investment

SC 13G/A 1 e617657sc13ga-steadymed.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4) * SteadyMed Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M84920103 (CUSIP Number) December 31,

STDY / SteadyMed Ltd. / FEDERATED INVESTORS INC /PA/ Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) STEADYMED, LTD. (Name of Issuer) COMMON STOCK (Title of Class of Securities) M84920103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this State

JOINT FILING AGREEMENT

EX-99.1 2 ss77165ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated January 26, 2018, with respect to the ordinary shares of SteadyMed Ltd. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the unders

STDY / SteadyMed Ltd. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment

SC 13D/A 1 ss77165sc13da.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* SteadyMed Ltd. (Name of Issuer) Ordinary Shares, nominal value NIS 0.01 per share (Title of Class of Securities) M84920103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2017 SteadyMed Ltd.

STDY / SteadyMed Ltd. DEF 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

SteadyMed Reports Third Quarter 2017 Financial Results and Provides Corporate Update

EX-99.1 2 a17-264081ex99d1.htm EX-99.1 Exhibit 99.1 SteadyMed Reports Third Quarter 2017 Financial Results and Provides Corporate Update SAN RAMON, Calif., November 13, 2017 — SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2017 (November 10, 2017) SteadyMed Ltd.

Amendment #2 to Lease Agreement, dated August 23, 2017, by and between the Registrant and Bechar and Sons (1983) Food Supply and Marketing Ltd.

EX-10.1 2 a17-206171ex10d1.htm EX-10.1 Exhibit 10.1 Amendment #2 to lease agreement from May 9, 2012 (The Amendment) Made and signed on August 23, 2017 Between: Bechar & Sons Food Supply and Marketing Ltd., Private Company 51-1008633 7 Beit Zuri Eliyahu Tel Aviv, 6912207 Israel (hereinafter: “the Lessor”) Of the one part And: SteadyMed Ltd., Company ID 513698928 Of 5 Oppenheimer St., Tamar Park Re

STDY / SteadyMed Ltd. 10-Q (Quarterly Report)

10-Q 1 a17-20617110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co

STDY / SteadyMed Ltd. PRE 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Other Events

8-K 1 a17-2129018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2017 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel 001-36889 Not applicable (State or other jurisdiction of incorpor

Company to meet and work with FDA to address issues raised

Exhibit 99.1 STEADYMED RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR TREVYENT? NEW DRUG APPLICATION Company to meet and work with FDA to address issues raised SAN RAMON, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) ? SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery

SteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporate Update Submitted New Drug Application for Trevyent for the Treatment of Pulmonary Arterial Hypertension On track for Mid-2018 U.S. Commercial Launch, Subject to FDA Approv

EX-99.1 2 a17-200261ex99d1.htm EX-99.1 Exhibit 99.1 SteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporate Update Submitted New Drug Application for Trevyent for the Treatment of Pulmonary Arterial Hypertension On track for Mid-2018 U.S. Commercial Launch, Subject to FDA Approval SAN RAMON, Calif., August 11, 2017 — SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2017 SteadyMed Ltd.

STDY / SteadyMed Ltd. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36889 Ste

STDY / SteadyMed Ltd. ESP

SteadyMed Ltd. 2603 Camino Ramon, Suite 350, San Ramon, California 94583 June 5, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Ada Sarmento Jeffrey Gabor Re: SteadyMed Ltd. Form S-3 Registration Statement Registration File No. 333-218217 Acceleration Request Requested Date: June 6, 2017 Requested Time: 4:00 P.M. East

SteadyMed S-3

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on May 24, 2017 Registration No.

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2017 SteadyMed Ltd.

SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate Update Raised $28.2 Million in Net Proceeds in a Private Placement Received a Favorable IPR Ruling Invalidating United Therapeutics’ ‘393 Patent Completed a Clinical Valida

EX-99.1 2 a17-130461ex99d1.htm EX-99.1 Exhibit 99.1 SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate Update Raised $28.2 Million in Net Proceeds in a Private Placement Received a Favorable IPR Ruling Invalidating United Therapeutics’ ‘393 Patent Completed a Clinical Validation Study for Trevyent® On Track to file a New Drug Application (NDA) for Trevyent for the Treatm

SteadyMed 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36889 St

STDY / SteadyMed Ltd. / Adage Capital Partners GP LLC - STEADYMED LTD. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SteadyMed Ltd. (Name of Issuer) Ordinary Shares, $0.01 nominal value per share (Title of Class of Securities) M84920103 (CUSIP Number) April 25, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whi

SteadyMed AMENDMENT NO. 1 (Activist Acquisition of More Than 5% of Shares)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* SteadyMed Ltd. (Name of Issuer) Ordinary Shares, nominal value NIS 0.01 per share (Title of Class of Securities) M84920103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VI LLC Samuel

JOINT FILING AGREEMENT

Exhibit N JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated April 28, 2017, with respect to the ordinary shares of SteadyMed Ltd.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

8-K 1 a17-1166618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2017 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel 001-36889 Not applicable (State or other jurisdiction of incorpora

Subscription Agreement, dated April 20, 2017, by and among SteadyMed Ltd. and Participants defined therein

EX-10.1 2 a17-116661ex10d1.htm EX-10.1 Exhibit 10.1 STEADYMED LTD. SUBSCRIPTION AGREEMENT Restricted Ordinary Shares and Warrants to purchase Restricted Ordinary Shares STEADYMED LTD., an Israeli incorporated company (the “Company”), is offering for sale an aggregate of up to $30,000,616.88 of (i) its restricted ordinary shares (the “Shares”), and (ii) warrants (the “Warrants”), in the form attach

SteadyMed Raises $30 Million in Private Placement SteadyMed prepares to file New Drug Application (NDA) for Trevyent® in Q2 2017 Financing provides capital for Trevyent commercial launch preparation

EX-99.1 3 a17-116661ex99d1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE SteadyMed Raises $30 Million in Private Placement SteadyMed prepares to file New Drug Application (NDA) for Trevyent® in Q2 2017 Financing provides capital for Trevyent commercial launch preparation SAN RAMON, Calif., April 21, 2017 — SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development

SteadyMed 10-K (Annual Report)

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a17-1007918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2017 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel 001-36889 Not applicable (State or other jurisdiction of incorpora

SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results

Exhibit 99.1 SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results SAN RAMON, Calif., March 29, 2017 ? SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its f

SteadyMed S-8

As filed with the U.S. Securities and Exchange Commission on March 29, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Delaware Not Applicable (State or other jurisdiction of (I.R.S. Employer Incorporation or organ

STDY / SteadyMed Ltd. / Flynn James E Passive Investment

SC 13G/A 1 e615809sc13ga-steadymed.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3) * SteadyMed Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M84920103 (CUSIP Number) December 31,

STDY / SteadyMed Ltd. / Flynn James E Passive Investment

SC 13G/A 1 e615763sc13ga-steadymed.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * SteadyMed Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M84920103 (CUSIP Number) December 31,

STDY / SteadyMed Ltd. / FEDERATED INVESTORS INC /PA/ Passive Investment

SC 13G/A 1 steadymed.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2* STEADYMED LTD. (Name of Issuer) COMMON STOCK (Title of Class of Securities) M84920103 (CUSIP Number) December 31, 2016 (Date of Event Which Requir

SteadyMed Outlines Strategic Goals and Priorities for 2017 and Provides Update on Trevyent Launch Plans

EX-99.1 2 a17-16311ex99d1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE SteadyMed Outlines Strategic Goals and Priorities for 2017 and Provides Update on Trevyent Launch Plans San Ramon, CA, January 9, 2017 — SteadyMed Therapeutics Ltd. (NASDAQ: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parent

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2017 SteadyMed Ltd.

SteadyMed ESP

SteadyMed Ltd. 2603 Camino Ramon, Suite 350, San Ramon, California 94583 December 20, 2016 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Mary Beth Breslin Jeffrey Gabor Re: SteadyMed Ltd. Registration Statement on Form S-3 Registration File No. 333-214707 Acceleration Request Requested Date: December 20, 2016 Requested Time: 4:30 P.M. Eastern Time Ladie

SteadyMed S-3/A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on December 16, 2016 Registration No.

SteadyMed ESP

Michael E. Tenta +1 650 843 5636 VIA EDGAR [email protected] December 16, 2016 United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Mary Beth Breslin Jeffrey Gabor Re: SteadyMed Ltd. Registration Statement on Form S-3 Filed November 18, 2016 File No. 333-214707 Dear Ms. Breslin and Mr. Gabor: On behalf of our client, SteadyMed Ltd., a company incorporate

SteadyMed S-3

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on November 18, 2016 Registration No.

STEADYMED LTD. , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20

EX-4.7 4 a2230286zex-47.htm EX-4.7 Exhibit 4.7 STEADYMED LTD. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20 STEADYMED LTD. FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between STEADYMED LTD., an Israeli company (the “Company”), and , a [corporation] [national banking association] organized and exi

STEADYMED LTD. , AS WARRANT AGENT FORM OF ORDINARY SHARE WARRANT AGREEMENT DATED AS OF [ ], 20

Exhibit 4.6 STEADYMED LTD. AND , AS WARRANT AGENT FORM OF ORDINARY SHARE WARRANT AGREEMENT DATED AS OF [ ], 20 STEADYMED LTD. FORM OF ORDINARY SHARE WARRANT AGREEMENT ORDINARY SHARE WARRANT AGREEMENT (this ?Agreement?), dated as of between STEADYMED LTD., an Israeli company (the ?Company?), and , a [corporation] [national banking association] organized and existing under the laws of and having a c

STEADYMED LTD., Issuer [TRUSTEE], Trustee Dated as of [·], 20 Debt Securities

Exhibit 4.3 STEADYMED LTD., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section 2.03

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2016 SteadyMed Ltd.

STEADYMED PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS

Exhibit 99.1 STEADYMED PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS SAN RAMON, Calif., November 14, 2016 (GLOBE NEWSWIRE) ? SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced i

SteadyMed 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3688

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 a16-2003518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2016 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel 001-36889 Not applicable (State or other jurisdiction of incorpo

Industrialization of Trevyent® for Pulmonary Arterial Hypertension Peter Noymer, Robert Zwolinski, Yasmin Noonoo SteadyMed Therapeutics, Inc., San Ramon, CA USA and SteadyMed Ltd., Rehovot, Israel Background Aseptic Filling Final Assembly Stability S

Exhibit 99.1 Industrialization of Trevyent® for Pulmonary Arterial Hypertension Peter Noymer, Robert Zwolinski, Yasmin Noonoo SteadyMed Therapeutics, Inc., San Ramon, CA USA and SteadyMed Ltd., Rehovot, Israel Background Aseptic Filling Final Assembly Stability Studies Introduction Trevyent® is a novel drug-device combination product being developed by SteadyMed based on the company’s proprietary

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2016 SteadyMed Ltd.

Eleventh Amended and Restated Articles of Association of SteadyMed Ltd.

Exhibit 3.1 ELEVENTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF STEADYMED LTD. 1. Company Name The name of the Company is SteadyMed Ltd. and in Hebrew ??????? ??''?? (the ?Company?). 2. Purpose 2.1. The purpose of the Company is to engage in any lawful act or activity for which companies may be organized under the Companies Law. 2.2. Pursuant to Section 11 of the Companies Law, the Company ma

STEADYMED LTD. AMENDED AND RESTATED 2009 STOCK INCENTIVE PLAN Approved by the Board of Directors of the Company on February 20, 2015. Approved by the shareholders of the Company on March 1, 2015. Amended by the Board of Directors of the Company on Au

EX-10.1 3 a16-197241ex10d1.htm EX-10.1 Exhibit 10.1 STEADYMED LTD. AMENDED AND RESTATED 2009 STOCK INCENTIVE PLAN Approved by the Board of Directors of the Company on February 20, 2015. Approved by the shareholders of the Company on March 1, 2015. Amended by the Board of Directors of the Company on August 8, 2016. Amended by the shareholders of the Company on October 5, 2016. 1. PURPOSE OF THE PLA

13,108,032 Shares Ordinary Shares

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

SteadyMed ESP

SteadyMed Ltd. 2603 Camino Ramon, Suite 350, San Ramon, California 94583 September 19, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Suzanne Hayes Jeffrey Gabor Re: SteadyMed Ltd. Form S-3 Registration Statement Registration File No. 333-213494 Acceleration Request Requested Date: September 21, 2016 Requested Time: 4

SteadyMed S-3

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on September 2, 2016 Registration No.

SteadyMed DEF 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

SteadyMed PRE 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

SteadyMed PRE 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

SteadyMed 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36889 Ste

SteadyMed 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36889 Ste

Form of Warrant

Exhibit 10.1 THIS WARRANT AND THE SECURITIES PURCHASABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. STEADYMED LTD. WARRANT da

Form of Warrant

Exhibit 10.1 THIS WARRANT AND THE SECURITIES PURCHASABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. STEADYMED LTD. WARRANT da

STEADYMED PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS

Exhibit 99.1 STEADYMED PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS SAN RAMON, Calif., August 15, 2016 (GLOBE NEWSWIRE) ? SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced i

STEADYMED PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS

Exhibit 99.1 STEADYMED PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS SAN RAMON, Calif., August 15, 2016 (GLOBE NEWSWIRE) ? SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced i

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2016 SteadyMed Ltd.

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2016 SteadyMed Ltd.

JOINT FILING AGREEMENT

Exhibit N JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 12, 2016, with respect to the ordinary shares of SteadyMed Ltd.

STDY / SteadyMed Ltd. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment

SC 13D 1 ss6484sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 SteadyMed Ltd. (Name of Issuer) Ordinary Shares, nominal value NIS $0.01 per share (Title of Class of Securities) M84920103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel II GP, L.P. OrbiMed Capit

JOINT FILING AGREEMENT

Exhibit N JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 12, 2016, with respect to the ordinary shares of SteadyMed Ltd.

Subscription Agreement, dated July 29, 2016, by and among SteadyMed Ltd. and Participants defined therein

Exhibit 10.1 Execution Copy STEADYMED LTD. SUBSCRIPTION AGREEMENT Restricted Ordinary Shares and Warrants to purchase Restricted Ordinary Shares STEADYMED LTD., an Israeli incorporated company (the ?Company?), is offering for sale an aggregate of up to $32,000,000 of (i) its restricted ordinary shares (the ?Shares?), and (ii) warrants (the ?Warrants?), in the form attached hereto as Exhibit A, to

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

8-K 1 a16-1579118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2016 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel 001-36889 Not applicable (State or other jurisdiction of incorporat

SteadyMed Raises up to $32 Million in Private Placement

EX-99.1 3 a16-157911ex99d1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE SteadyMed Raises up to $32 Million in Private Placement SAN RAMON, Calif, July 29, 2016 — SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has entered in

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 SteadyMed Ltd.

SteadyMed Provides Corporate Update and Reports First Quarter 2016 Financial Results

EX-99.1 2 a16-110631ex99d1.htm EX-99.1 Exhibit 99.1 SteadyMed Provides Corporate Update and Reports First Quarter 2016 Financial Results SAN RAMON, Calif., May 11, 2016 — SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate upda

SteadyMed 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36889 St

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2016 SteadyMed Ltd.

SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results

Exhibit 99.1 SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results SAN RAMON, Calif., March 29, 2016 ? SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its f

SteadyMed 10-K (Annual Report)

Use these links to rapidly review the document TABLE OF CONTENTS STEADYMED LTD. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2015 IN U.S. DOLLARS INDEX Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year e

PatchPump Technology INJECTABLE DRUG DELIVERY March 8, 2016 Assaf Shaked

Exhibit 99.1 PatchPump Technology INJECTABLE DRUG DELIVERY March 8, 2016 Assaf Shaked This presentation and the accompanying oral commentary (if any) contain both historical and forward-looking statements which are based on current expectations, estimates and projections. Statements that are not historical facts are forward-looking statements and typically are identified by words like ?may,? ?beli

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2016 SteadyMed Ltd.

STDY / SteadyMed Ltd. / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

STDY / SteadyMed Ltd. / FEDERATED INVESTORS INC /PA/ Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* STEADYMED LTD. (Name of Issuer) COMMON STOCK (Title of Class of Securities) M84920103 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statem

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2015 SteadyMed Ltd.

STEADYMED REPORTS RECENT DEVELOPMENTS AND THIRD QUARTER 2015 FINANCIAL RESULTS MANAGEMENT TO HOST WEBCAST AND CONFERENCE CALL TODAY AT 4:30 P.M. ET

Exhibit 99.1 FOR IMMEDIATE RELEASE STEADYMED REPORTS RECENT DEVELOPMENTS AND THIRD QUARTER 2015 FINANCIAL RESULTS MANAGEMENT TO HOST WEBCAST AND CONFERENCE CALL TODAY AT 4:30 P.M. ET SAN RAMON, Calif., November 12, 2015 ? SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delive

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2015 SteadyMed Ltd.

STEADYMED PROVIDES INSIGHTS ON RECENT CORPORATE DEVELOPMENTS AND REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS MANAGEMENT TO HOST WEBCAST AND CONFERENCE CALL TODAY AT 4:30 P.M. EDT

Exhibit 99.1 FOR IMMEDIATE RELEASE STEADYMED PROVIDES INSIGHTS ON RECENT CORPORATE DEVELOPMENTS AND REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS MANAGEMENT TO HOST WEBCAST AND CONFERENCE CALL TODAY AT 4:30 P.M. EDT SAN RAMON, Calif., August 13, 2015 ? SteadyMed Ltd. (NASDAQ: STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseas

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 SteadyMed Ltd.

SteadyMed DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2015 SteadyMed Ltd.

SteadyMed DEF 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2015 SteadyMed Ltd.

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2015 SteadyMed Ltd.

Third Lease Addendum, dated May 29, 2015, by and between SteadyMed Therapeutics, Inc. and Annabel Investment Company

Exhibit 10.2 THIRD LEASE ADDENDUM THIS THIRD LEASE ADDENDUM IS MADE AND ENTERED INTO THIS 29TH DAY OF MAY, 2015, BY AND BETWEEN ANNABEL INVESTMENT COMPANY, A CALIFORNIA LIMITED PARTNERSHIP (HEREINAFTER REFERRED TO AS ?LANDLORD?) AND STEADYMED THERAPEUTICS, INC. (HEREINAFTER REFERRED TO AS ?TENANT?). IT IS AGREED BETWEEN LANDLORD AND TENANT TO MODIFY THE LEASE DATED SEPTEMBER 20, 2012, INCLUDING AL

First Lease Addendum dated May 29, 2015, by and between SteadyMed Therapeutics, Inc. and Sunset Land Company, LLC

Exhibit 10.1 FIRST LEASE ADDENDUM THIS FIRST LEASE ADDENDUM IS MADE AND ENTERED INTO THIS 29TH DAY OF MAY, 2015, BY AND BETWEEN SUNSET LAND COMPANY, LLC, A CALIFORNIA LIMITED LIABILITY COMPANY (HEREINAFTER REFERRED TO AS “LANDLORD”) AND STEADYMED THERAPEUTICS, INC. (HEREINAFTER REFERRED TO AS “TENANT”). IT IS AGREED BETWEEN LANDLORD AND TENANT TO MODIFY THE LEASE DATED MAY 1, 2015 (HEREINAFTER REF

STEADYMED REPORTS RECENT DEVELOPMENTS, FINANCIAL HIGHLIGHTS AND FIRST QUARTER 2015 FINANCIAL RESULTS

EX-99.1 2 a15-116061ex99d1.htm EX-99.1 Exhibit 99.1 STEADYMED REPORTS RECENT DEVELOPMENTS, FINANCIAL HIGHLIGHTS AND FIRST QUARTER 2015 FINANCIAL RESULTS SAN RAMON, Calif., May 14, 2015 — SteadyMed Ltd. (NASDAQ: STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs, today announced recent de

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015 SteadyMed Ltd.

SteadyMed 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2015 SteadyMed Ltd.

Bishop Ranch Building Lease, dated May 1, 2015, by and between SteadyMed Therapeutics, Inc. and Sunset Land Company, LLC.

Exhibit 10.1 BISHOP RANCH BISHOP RANCH BUILDING LEASE A Sunset Development Project 2600 Camino Ramon, Suite 201 | San Ramon, CA 94583 Tel 925 277 1700 Fax 926.277.1309 www.bishiopranch.com STEADYMED THERAPEUTICS, INC. BISHOP RANCH - BUILDING LEASE TABLE OF CONTENTS Page 1. PREMISES 1 2. TERM 1 2.1 Term 1 2.2 Delay in Commencement 1 2.3 Acknowledgment of Commencement Date 2 3. RENT 2 3.1 Base Rent

STDY / SteadyMed Ltd. / FEDERATED INVESTORS INC /PA/ Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* STEADYMED LTD. (Name of Issuer) COMMON STOCK (Title of Class of Securities) M84920103 (CUSIP Number) March 31, 2015 (Date of Event Which Requires Filing of this Statement)

STDY / SteadyMed Ltd. / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

SteadyMed S-8

S-8 1 a15-77091s8.htm S-8 As filed with the U.S. Securities and Exchange Commission on March 26, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Delaware Not Applicable (State or other jurisdiction of (I.R.S. Emplo

4,700,000 Shares Ordinary shares

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No.

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Jonathan M.

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Jonathan M.

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of David W.

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Jonathan M.

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Jonathan M.

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Jonathan M.

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Jonathan M.

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Jonathan M.

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Jonathan M.

Joint Filer Information

Joint Filer Information Names: Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P. Address: 780 Third Avenue, 37th Floor New York, NY 10017 Designated Filer: James E. Flynn Issuer and Ticker Symbol: SteadMed Ltd. [STDY] Date of Event Requiring Statement: March 19, 2015 The undersigned,

SteadyMed S-1MEF

As filed with the Securities and Exchange Commission on March 19, 2015. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Indust

SteadyMed 8-A12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 SteadyMed Ltd.

SteadyMed S-1/A

As filed with the Securities and Exchange Commission on March 16, 2015. Registration No. 333-201949 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SteadyMed Ltd. (Exact name of registrant as specified in its charter) Israel (State or other jurisdiction of incorporation or organization) 2834

SteadyMed ESP

March 16, 2015 VIA EMAIL AND EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

SteadyMed ESP

Michael E. Tenta T: +1 650 843 5636 VIA EDGAR [email protected] March 9, 2015 United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Re: SteadyMed Ltd. Registration Statement on Form S-1 Filed February 6, 2015 File No. 333-201949 Dear Mr. Riedler: On behalf of our client, SteadyMed Ltd., a company incorporated under the laws of Israel (t

SteadyMed S-1/A

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on March 9, 2015.

STDY / SteadyMed Ltd. CORRESP - -

CORRESP 1 filename1.htm *FOIA Confidential Treatment Request* Confidential Treatment Requested by SteadyMed Ltd. in connection with Registration Statement on Form S-1 filed on February 6, 2015 Michael E. Tenta T: +1 650 843 5636 [email protected] VIA EDGAR March 3, 2015 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P

Lease, dated September 20, 2012, by and between the Registrant and Annabel Investment Company

Exhibit 10.4 BISHOP RANCH EXECUTION [BISHOP RANCH LOGO] ORIGINAL BISHOP RANCH BUILDING LEASE A Sunset Development Project One Annabel Lane, Suite 201 | San Ramon, CA 94583 tel 925.866.0100 fax 925.866.1330 www.bishopranch.com LEASE THIS LEASE made as of this 20th day of September, 2012, between LANDLORD, whose full name and address is set forth below, and TENANT, whose full name and address is set

Loan and Security Agreement, dated February 20, 2013, by and between SteadyMed Therapeutics, Inc. and Square 1 Bank

Exhibit 10.7 STEADYMED THERAPEUTICS, INC. LOAN AND SECURITY AGREEMENT [SQUARE 1 BANK LOGO] This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of February 20, 2013, by and between Square 1 Bank (“Bank”) and SteadyMed Therapeutics, Inc. (“Borrower”). RECITALS Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement

STDY / SteadyMed Ltd. CORRESP - -

Michael E. Tenta T: +1 650 843 5636 [email protected] VIA EDGAR February 6, 2015 United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Re: SteadyMed Ltd. Amendment No. 3 to Draft Registration Statement on Form S-1 Submitted December 24, 2014 CIK No. 0001619087 Dear Mr. Riedler: On behalf of our client, SteadyMed Ltd., a company incorpor

First Amendment to Loan and Security Agreement, dated March 20, 2013, by and between SteadyMed Therapeutics, Inc. and Square 1 Bank

Exhibit 10.8 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (the “Amendment”), is entered into as of March 20, 2013, by and between SQUARE I BANK (the “Bank”) and STEADYMED THERAPEUTICS, INC. (the “Borrower”). RECITALS Borrower and Bank are parties to that Loan and Security Agreement dated as of February 20, 2013 (as amended from time to time, th

SUPPLY AGREEMENT

Exhibit 10.3 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. SUPPLY AGREEMENT This Agreement (“Agreement”) is entered into as of 10th day of December 2013, (the “Effective Date”) by and between [*], a company incorp

STDY / SteadyMed Ltd. S-1 - Registration Statement - S-1

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on February 6, 2015.

Fourth Amended Investor Rights Agreement, dated February 24, 2014, by and among the Registrant and certain of its shareholders

Exhibit 4.2 STEADYMED LTD. FOURTH AMENDED INVESTORS RIGHTS AGREEMENT This Fourth Amended Investors Rights Agreement (the “Agreement”) is made as of February 24th, 2014, by and among (i) SteadyMed Ltd., an Israeli company (the “Company”), (ii) the persons and entities identified in Schedule 1 hereto (individually or collectively) referred to herein as “Preferred E Holder(s)” (iii) the persons and e

Lease Agreement, dated May 9, 2012, by and between the Registrant and Bacher and Sons (1983) and Food Supply and Marketing Ltd.

Exhibit 10.6 Lease Agreement Made and signed in Ramat Gan on May 9, 2012 Between: Bechar & Sons (1983) Food Supply and Marketing Ltd., Private Company 51-1008633 At Adv. Avi Bechar, of 9 Hagilad St., Ramat Gan (hereinafter: “the Lessor”) Of the one part And: SteadyMed Ltd., Private Company 513698928 Of 5 Oppenheimer St., Tamar Park Rehovot (hereinafter: “the Lessee”) Of the other part Whereas The

First Lease Addendum, dated June 11, 2013, by and between the Registrant and Annabel Investment Company

Exhibit 10.5 FIRST LEASE ADDENDUM THIS. FIRST LEASE ADDENDUM IS MADE AND ENTERED INTO THIS 11th DAY OF JUNE, 2013, BY AND BETWEEN ANNABEL INVESTMENT COMPANY, A CALIFORNIA LIMITED PARTNERSHIP (HEREINAFTER REFERRED TO AS “LANDLORD”) AND STEADYMED THERAPEUTICS, INC. (HEREINAFTER REFERRED TO AS “TENANT”). IT IS AGREED BETWEEN LANDLORD AND TENANT TO MODIFY THE LEASE DATED SEPTEMBER 20, 2012 (HEREINAFTE

SteadyMed Ltd. 2013 Stock Incentive Subplan and forms of agreements relating thereto

EX-10.2 3 a2222892zex-102.htm EX-10.2 Exhibit 10.2 APPENDIX A TO THE 2009 STOCK OPTION PLAN STEADYMED, LTD. 2013 STOCK INCENTIVE SUBPLAN ARTICLE I PURPOSE The purpose of this 2013 Stock Incentive Subplan (the “Plan”) of SteadyMed, Ltd., an Israeli corporation (the “Company”), is to specify the terms under which Options under the 2009 Stock Option Plan may be granted to individuals performing servi

List of Subsidiaries of SteadyMed Ltd.

Exhibit 21.1 List of Subsidiaries of SteadyMed Ltd. Subsidiaries Incorporation SteadyMed Therapeutics, Inc. Delaware, United States SteadyMed U.S. Holdings, Inc. Delaware, United States

STDY / SteadyMed Ltd. DRSLTR - -

Michael E. Tenta T: +1 650 843 5636 [email protected] VIA EDGAR December 24, 2014 United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Re: SteadyMed Ltd. Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted November 12, 2014 CIK No. 0001619087 Dear Mr. Riedler: On behalf of our client, SteadyMed Ltd., a company incorpo

STDY / SteadyMed Ltd. DRS/A - -

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Confidential draft no.

Lease Agreement Made and signed in Ramat Gan on May 9, 2012

Exhibit 10.6 Lease Agreement Made and signed in Ramat Gan on May 9, 2012 Between: Bechar & Sons (1983) Food Supply and Marketing Ltd., Private Company 51-1008633 At Adv. Avi Bechar, of 9 Hagilad St., Ramat Gan (hereinafter: “the Lessor”) Of the one part And: SteadyMed Ltd., Private Company 513698928 Of 5 Oppenheimer St., Tamar Park Rehovot (hereinafter: “the Lessee”) Of the other part Whereas The

STDY / SteadyMed Ltd. DRSLTR - -

Michael E. Tenta VIA EDGAR T: +1 650 843 5636 [email protected] November 12, 2014 United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Re: SteadyMed Ltd. Draft Registration Statement on Form S-1 Submitted September 17, 2014 CIK No. 0001619087 Dear Mr. Riedler: On behalf of our client, SteadyMed Ltd., a company incorporated under the la

STDY / SteadyMed Ltd. DRS/A - -

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Confidential draft no.

SUPPLY AGREEMENT

Exhibit 10.3 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. SUPPLY AGREEMENT This Agreement (“Agreement”) is entered into as of 10th day of December 2013, (the “Effective Date”) by and between [*], a company incorp

STEADYMED THERAPEUTICS, INC. LOAN AND SECURITY AGREEMENT

Exhibit 10.7 STEADYMED THERAPEUTICS, INC. LOAN AND SECURITY AGREEMENT [SQUARE 1 BANK LOGO] This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of February 20, 2013, by and between Square 1 Bank (“Bank”) and SteadyMed Therapeutics, Inc. (“Borrower”). RECITALS Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement

EIGHTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION STEADYMED LTD. AMENDED AND RESTATED AS OF FEBRUARY 17TH , 2014

Exhibit 3.1 EIGHTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF STEADYMED LTD. AMENDED AND RESTATED AS OF FEBRUARY 17TH , 2014 1. Company Name The name of the Company is SteadyMed Ltd. and in Hebrew (the “Company”) 2. Purpose 2.1. The purpose of the Company is to engage in any lawful act or activity for which companies may be organized under the Israeli Companies Law (the “Companies Law”) 2.2.

FIRST LEASE ADDENDUM

Exhibit 10.5 FIRST LEASE ADDENDUM THIS. FIRST LEASE ADDENDUM IS MADE AND ENTERED INTO THIS 11th DAY OF JUNE, 2013, BY AND BETWEEN ANNABEL INVESTMENT COMPANY, A CALIFORNIA LIMITED PARTNERSHIP (HEREINAFTER REFERRED TO AS “LANDLORD”) AND STEADYMED THERAPEUTICS, INC. (HEREINAFTER REFERRED TO AS “TENANT”). IT IS AGREED BETWEEN LANDLORD AND TENANT TO MODIFY THE LEASE DATED SEPTEMBER 20, 2012 (HEREINAFTE

APPENDIX A TO THE 2009 STOCK OPTION PLAN STEADYMED, LTD. 2013 STOCK INCENTIVE SUBPLAN ARTICLE I

EX-10.2 5 filename5.htm Exhibit 10.2 APPENDIX A TO THE 2009 STOCK OPTION PLAN STEADYMED, LTD. 2013 STOCK INCENTIVE SUBPLAN ARTICLE I PURPOSE The purpose of this 2013 Stock Incentive Subplan (the “Plan”) of SteadyMed, Ltd., an Israeli corporation (the “Company”), is to specify the terms under which Options under the 2009 Stock Option Plan may be granted to individuals performing services on behalf

STEADYMED LTD. FOURTH AMENDED INVESTORS RIGHTS AGREEMENT

Exhibit 4.2 STEADYMED LTD. FOURTH AMENDED INVESTORS RIGHTS AGREEMENT This Fourth Amended Investors Rights Agreement (the “Agreement”) is made as of February 24th, 2014, by and among (i) SteadyMed Ltd., an Israeli company (the “Company”), (ii) the persons and entities identified in Schedule 1 hereto (individually or collectively) referred to herein as “Preferred E Holder(s)” (iii) the persons and e

ORIGINAL BISHOP RANCH BUILDING LEASE A Sunset Development Project One Annabel Lane, Suite 201 | San Ramon, CA 94583 tel 925.866.0100 fax 925.866.1330 www.bishopranch.com

Exhibit 10.4 BISHOP RANCH EXECUTION [BISHOP RANCH LOGO] ORIGINAL BISHOP RANCH BUILDING LEASE A Sunset Development Project One Annabel Lane, Suite 201 | San Ramon, CA 94583 tel 925.866.0100 fax 925.866.1330 www.bishopranch.com LEASE THIS LEASE made as of this 20th day of September, 2012, between LANDLORD, whose full name and address is set forth below, and TENANT, whose full name and address is set

List of Subsidiaries of SteadyMed Ltd.

Exhibit 21.1 List of Subsidiaries of SteadyMed Ltd. Subsidiaries Incorporation SteadyMed Therapeutics, Inc. Delaware, United States

[SteadyMed logo] STEADYMED LTD. 2009 STOCK OPTION PLAN

EX-10.1 4 filename4.htm Exhibit 10.1 [SteadyMed logo] STEADYMED LTD. 2009 STOCK OPTION PLAN This plan, as amended from time to time, shall be known as the SteadyMed Ltd. 2009 Stock Option Plan (the “Plan”). All capitalized terms used herein shall have the respective meanings assigned to them in Section 4 below, unless otherwise indicated. 1. PURPOSE OF THE PLAN The purpose of this Plan is to assis

STDY / SteadyMed Ltd. DRS - -

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 17, 2014.